Mag. Dr. Günter Klambauer



Institute for Machine Learning Johannes Kepler University Linz Altenberger Str. 69, 4040 Linz, Austria

E-mail: klambauer@ml.jku.at

https://orcid.org/0000-0003-2861-5552

https://scholar.google.at/citations?user=rb2AvxIAAAAJ&hl=de

Education

Since 2019: Tenure-track professorship "Al and Drug Discovery",

LIT AI Lab & Institute for Machine Learning, Johannes Kepler University Linz.

2017–2019: Group Leader "Al and Drug Discovery",

LIT AI Lab & Institute for Machine Learning, Johannes Kepler University Linz.

2014–2017: Postdoc Researcher,

Institute of Bioinformatics, Johannes Kepler University Linz.

04/2014 Dr. rer. nat. (PhD) degree, Johannes Kepler University Linz,

Thesis: Machine Learning Techniques for the Analysis of High-Throughput DNA and

RNA Sequencing Data, Supervisor: Sepp Hochreiter. Passed with distinction.

2010-2014: PhD Study Bioinformatics,

Johannes Kepler University Linz, Supervisor: Sepp Hochreiter.

2007-2010: Master Study Bioinformatics,

Johannes Kepler University Linz.

2007-2009: Secondary School Teacher,

BORG Linz and BORG Bad Leonfelden.

07/2007: Mag. rer. nat. (MSc) Degree, University of Vienna,

Thesis: Topics in Complex Analysis: Laurent-Series, Conformal Mappings and Residue-Theory, Supervisor: Maria Hoffmann-Ostenhof. Passed with distinction.

09/2006 - 02/2007: Studies Abroad, Universitá degli Studi Padova.

2001-2007: Mathematics and Biology Diploma-Studies, University of Vienna.

Acquired Funding

- 3/2018 8/2020: DeepToxGen: Deep Learning for in-silico toxicogenetics testing, Project funded by LIT (Linz Institute of Technology), Volume: 200K.
- 10/2019 9/2021: AI-SNN: Self-normalizing neural networks as enablers of functional modularity in I are AI systems, Project funded by LIT (Linz Institute of Technology), Volume: 210K.
- 9/2019 8/2021: MadeSMART: Deep Learning for in-silico toxicogenetics testing, Project funded by Janssen Pharmaceuticals, Volume: 400K.
- 10/2019 9/2021: UCBnet: Driving drug design with deep multimodal and multi-task learning, Project funded by UCB Biopharma, Volume: 470K.